Regenxbio Inc RGNX

NAS: RGNX | ISIN: US75901B1070 30/04/2025

9,610 USD (+2,13%)

(+2,13%) 30/04/2025

Grafiek Regenxbio Inc

Grafiek Regenxbio Inc

1 dag1d 2,13%
1 week1w 4,46%
1 maand1m 42,16%
3 maanden3m 22,89%
6 maanden6m 9,33%
1 jaar1j -40,68%
5 jaar5j -73,64%

Regenxbio Inc in het nieuws

Toon enkel gratis nieuws

30 april 2025 · REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights · Persbericht

19 maart 2025 · Regenxbio Reports Positive Biomarker Data From Affinity Duchenne® Trial Of Rgx-202 Gene Therapy · Persbericht

13 maart 2025 · REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates · Persbericht

10 maart 2025 · REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

4 maart 2025 · REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases · Persbericht

3 september 2024 · REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect · Persbericht

29 augustus 2024 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

27 augustus 2024 · REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium · Persbericht

8 augustus 2024 · REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference · Persbericht

1 augustus 2024 · REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

Profiel Regenxbio Inc

Gezondheidstechnologie

Productie van biologische producten

Website: regenxbio.com

Hoofdzetel: Rockville, Maryland Verenigde Staten

CEO: Kenneth Mills

Werknemers: 408

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe